atai Life Sciences’ Perception Neuroscience’s PCN-101 (R-Ketamine) Demonstrates Tolerability in Phase 1 Single Ascending Dose Study

February 19, 2021 Articles 3:02 pm

Perception Neuroscience, an atai Life Sciences biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced positive data from its first Phase 1 clinical study demonstrating the safety and tolerability of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine that is being developed for therapeutic treatment of psychiatric illnesses such as Treatment Resistant Depression.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on atai and innovations in the space.

Email
submit